ArticleScientific reports2017
Ciproxifan, a histamine H
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Design, Synthesis, and Evaluation of Coumarin-Rasagiline Hybrids as Multifunctional Neuroprotective Agents.ChemMedChem · 2026Article
- Emerging Roles of Rivastigmine Derivatives Bearing Antioxidant Motifs as Multi-Target Agents for the Management of Neurodegenerative Diseases.International journal of molecular sciences · 2026Article
- The central histaminergic system slows visual processing in the retina and lateral geniculate nucleus of awake mice.PLoS biology · 2025Article
- Novel applications of sleep pharmacology as delirium therapeutics.Sleep medicine reviews · 2025Review
- Targeting Microglia in Neuroinflammation: H3 Receptor Antagonists as a Novel Therapeutic Approach for Alzheimer's Disease, Parkinson's Disease, and Autism Spectrum Disorder.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Mechanistic Insights into the Neurotoxicity of 2,5-Dimethoxyphenethylamines (2C) and CorrespondingJournal of xenobiotics · 2024Article
- Rivastigmine-Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases.International journal of molecular sciences · 2023Article
- Dual Targeting Ligands-Histamine HPharmaceutics · 2022Article
- Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine DMolecular pharmaceutics · 2022Article
- Molecular Modeling and Experimental Evaluation of Non-Chiral Components of Bergamot Essential Oil with Inhibitory Activity against Human Monoamine Oxidases.Molecules (Basel, Switzerland) · 2022Article
- Fine-Tuning the Biological Profile of Multitarget Mitochondriotropic Antioxidants for Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2021Article
- Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine HScientific reports · 2020Article
- The Dual-Active Histamine HInternational journal of molecular sciences · 2020Article
- Article
- Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment.Oncology research · 2019Article
- Design, synthesis, and biological evaluation of novel iso-flavones derivatives as HJournal of enzyme inhibition and medicinal chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ciproxifan is a well-investigated histamine H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.